These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 35076703)

  • 1. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
    Dang UJ; Damsker JM; Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans NM; Haberlová J; Straub V; Mengle-Gaw L; Schwartz BD; Harper A; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster RI; Mcmillan HJ; Kuntz N; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez JJ; Nascimento-Osorio A; Niks EH; De Groot IJM; Katsalouli M; Van Den Anker JN; Ward LM; Leinonen M; D'Alessandro AL; Hoffman EP
    Neurology; 2024 Mar; 102(5):e208112. PubMed ID: 38335499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
    Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR;
    Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP
    J Neuromuscul Dis; 2023; 10(3):439-447. PubMed ID: 37005891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy.
    Grounds MD; Lloyd EM
    J Neuromuscul Dis; 2023; 10(6):1013-1030. PubMed ID: 37927274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.
    Mavroudis PD; van den Anker J; Conklin LS; Damsker JM; Hoffman EP; Nagaraju K; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2019 Jul; 59(7):979-988. PubMed ID: 30742306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
    Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
    Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.
    Li X; Conklin LS; van den Anker J; Hoffman EP; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2020 Oct; 60(10):1385-1396. PubMed ID: 32434278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A Systematic Review.
    Pascual-Morena C; Lucerón-Lucas-Torres M; Martínez-García I; Rodríguez-Gutiérrez E; Patiño-Cardona S; Sequí-Domínguez I
    Paediatr Drugs; 2024 Nov; 26(6):695-707. PubMed ID: 39331339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids.
    Duong T; Canbek J; Fernandez-Fernandez A; Henricson E; Birkmeier M; Siener C; Tesi Rocha C; McDonald C; Gordish-Dressman H;
    J Neuromuscul Dis; 2022; 9(1):147-159. PubMed ID: 34719507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy.
    Rutter MM; Wong BL; Collins JJ; Sawnani H; Taylor MD; Horn PS; Backeljauw PF
    Muscle Nerve; 2020 May; 61(5):623-631. PubMed ID: 32108355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy.
    Li X; Sabbatini D; Pegoraro E; Bello L; Clemens P; Guglieri M; van den Anker J; Damsker J; McCall J; Dang UJ; Hoffman EP; Jusko WJ
    J Clin Pharmacol; 2024 Sep; 64(9):1130-1140. PubMed ID: 38682893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis.
    Elhalag RH; Motawea KR; Talat NE; Rouzan SS; Shah J
    Front Neurol; 2023; 14():1107474. PubMed ID: 36816559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.